Multiple myeloma

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Blade J ^a   Teresa Cibeira, M ^a   Fernandez de Larrea C ^a   Rosinol L ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Allogeneic stem cell transplantation; Monoclonal gammopathy; Multiple myeloma; 2 microglobulin

Indexed keywords

ACICLOVIR; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; GLUCOCORTICOID; LENALIDOMIDE; M PROTEIN; MELPHALAN; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; VINCRISTINE; VORINOSTAT;

AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; CANCER STAGING; CHROMOSOME ANALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; JAW OSTEONECROSIS; KARNOFSKY PERFORMANCE STATUS; MINIMAL RESIDUAL DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78649337573     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq363     Document Type: Conference Paper

References (67)

1. Bladé J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345-351.
2. Landgren O, Kyle RA, Pfeiffer RM et al. Monoclonal gammopathy of undetermined significant (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
3. Weis BM, Abadie J, Verma P et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5442.
4. Bladé J, Rosiñol L, Cibeira MT. Are all myelomas preceded by MGUS? Blood 2009; 113(22): 5370.
5. Bladé L, Rosiñol L, Cibeira MT, Fernández de Larrea C. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008; 22: 1651-1657.
6. International Myeloma Working Group. Criteria for classification of monoclonal gammopathies, multiple myeloma and related disorders. Br J Haematol 2003; 121: 749-757.
7. Bladé J, Dimopoulos MA, Rosiñol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome and follow-up recommendations. J Clin Oncol 2010; 28: 690-697.
8. Greipp PR, San Miguel JF, Durie BGM et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
9. Bladé, Rosiñol L, Cibeira MT. Prognostic factors for multiple myeloma in the era of novel agents. Ann Oncol 2008; 19 (Suppl 7): vii117-vii120.
10. Avet-Loiseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489-3495.
11. Gutié rrez N, Castellanos MV, Martín ML et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant prognostic factor, whereas Rb deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007; 21: 143-150.
12. Carrasco R, Tonon G, Huang Y et al. High-resolution genomic profiles defines distinct clinico-pathogenetic subgroups of multiple myeloma. Cancer Cell 2006; 4: 313-325.
13. Avet-Loiseau H, Li C, Magranyes F et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27: 4585-4590.
14. Jagannath S, Richardson PG, Sonneveld P et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151-157.
15. Bladé J, Esteve J, Rives S et al. High-dose therapy autotransplantation/intensification vs. continued standard chemotherapy in multiple myeloma. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845-849.
16. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
17. Nadal E, Giné E, Bladé J et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33: 61-64.
18. Lahuerta JJ, Mateos MV, Martínez-López J et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782.
19. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399-1406.
20. Paiva B, Vidriales MB, Cerveró J et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017-4023.
21. Ladetto M, Pagliano G, Ferrero S et al. Major tumor shrinking and persistent molecular remission after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077-2084.
22. Chronic Leukemia Myeloma Task Force. National Cancer Institute. Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 145-158.
23. Alexanian R, Bonnet L, Gehan E et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382-389.
24. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
25. Durie BG, Harousseau JL, San Miguel JF et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
26. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008; 26: 480-492.
27. Stewart AK, Richardson PG, San Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009; 114: 5436-5443.
28. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655-3663.
29. Rosiñol L, Cibeira MT, Bladé J et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832-836.
30. Harousseau JL, Attal M, Leleu X et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 2006; 91: 1498-1505.
31. Rosiñol L, Oriol A, Mateos MV et al. A phase II trial of alternating bortezomib and dexamethasone as induction regimen prior to autologous stem cell transplantation in younger patients with multiple myeloma. J Clin Oncol 2007; 25: 4452-4458.
32. Popat R, Oakervee HE, Hallam S et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008; 141: 512-516.
33. Cavo M, Tacchetti P, Patriarca F et al. A phase III study of double autotransplantation incorporating bortezomib/thalidomide/dexamethasone (VTD) or thalidomide/dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. Blood 2009; 114: 148 (Abstr 351).
34. Rosiñol L, Cibeira MT, Martínez J et al. Thalidomide/dexamethasone (TD) vs. bortezomibthalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcade as induction regimens prior autologous stem cell transplantation in multiple myeloma. Results of a phase III PETHEMA/GEM. Blood 2009; 114: 59 (Abstr 130).
35. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 108: 3289-3294.
36. Spencer A, Prince HM, Roberts AW et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem cell transplantation procedure. J Clin Oncol 2009; 27: 1788-1793.
37. Garban F, Attal M, Michallet M et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high risk de novo multiple myeloma. Blood 2006; 107: 3474-3480.
38. Rosiñol L, Pérez Simón JA, Sureda A et al. A prospective PETHEMA study of tandem autologous transplantation versus allograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591-3593.
39. Bruno B, Rotta M, Patriarca F et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009; 113: 3375-3382.
40. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone or reduced-intensity autologous stem cell transplant in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet 2007; 370: 1209-1218.
41. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-3670.
42. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: a randomized controlled trial. Lancet 2006; 367: 825-831.
43. Waage A, Gimsing P, Juliusson G et al. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled phase III trial. Blood 2007; 110: 32 (Abstr 77).
44. Wiejermans P, Schafsme M, van Norden N et al. Melphalan/prednisone/thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch cooperative Group HOVON 48 Study. Blood 2008; 112: 241 (Abstr).
45. Palumbo A, Dimopoulos MA, Delforge M et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with multiple myeloma. Blood 2009; 114: 253 (Abstr 613).
46. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment for multiple myeloma. N Engl J Med 2008; 350: 906-917.
47. Ludwig H, Hajek R, Tóthová E et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009; 113: 3435-3441.
48. Rajkumar SV, Rosiñol L, Hussein M et al. A multicenter, randomized, double-blinded, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26: 2171-2177.
49. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Group. J Clin Oncol 2006; 24: 431-436.
50. Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized clinical trial. Lancet Oncol 2010; 11: 29-37.
51. Bladé J, Rosiñol L. Changing paradigms in the treatment of multiple myeloma. Haematologica 2009; 94: 163-166.
52. Palumbo A, Facon T, Sonneveld P et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-3977.
53. Richardson PG, Barlogie B, Berenson J et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
54. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
55. Richardson PG, Sonneveld P, Schuster MW et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557-3560.
56. Orlowski RZ, Nagler A, Sonneveld P et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892-3901.
57. Richardson PG, Jagennath S, Hussein M et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114: 772-778.
58. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
59. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
60. Bladé J, Rosiñol L. Advances in therapy of multiple myeloma. Curr Op Oncol 2008; 20: 697-704.
61. Podar K, Chauban D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24.
62. Ocio EM, Mateos MV, Maiso P, Pandiella A, San Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase i/ii clinical findings. Lancet Oncol 2008; 27: 120-126.
63. Bladé J, Cibeira MT, Rosiñol L. Novel drugs for the treatment of multiple myeloma. Haematologica 2010; 95: 702-704.
64. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
65. Delforge M, Bladé J, Dimopoulos MA et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010 (in press).
66. Terpos E, Sezer O, Croucher PI et al. The use of biphosphonates in multiple myeloma: recommendations by an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20: 1303-1317.
67. Rizzo JD, Somerfield MR, Hagerty KL et al. Use of epoetin and darboepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26: 132-149.